British Dragon
British Dragon
Tesamorelin 5 mg
Product Information Compound Details
Active Substance Tesamorelin Growth Hormone-Releasing Hormone (GHRH) Analog
5 mgStrength 5 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer British Dragon
Shipping :
International
U.S. Domestic
Out of stock
- Overview
- Profile
- Usage
- Safety
- Shipping
- Storage
- FAQ
- Reviews
Product Overview
Tesamorelin 5 mg by British Dragon
Tesamorelin 5 mg is a lyophilized growth hormone-releasing hormone (GHRH) analog research product manufactured by British Dragon and supplied as a 5 mg/vial powder in a 2 mL vial.
Tesamorelin Injectable
Tesamorelin 5 mg contains tesamorelin acetate, a synthetic 44-amino-acid peptide corresponding to the full sequence of endogenous human growth hormone-releasing hormone (GHRH). Tesamorelin is the active ingredient in EGRIFTA and EGRIFTA SV, FDA-approved medications indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Tesamorelin works by binding to GHRH receptors on the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone. Unlike exogenous growth hormone administration, tesamorelin relies on the body's own pituitary function, potentially allowing natural feedback mechanisms to regulate GH levels. This mechanism has made it a subject of interest in non-medical bodybuilding contexts for its potential effects on visceral fat reduction and body composition.
The FDA-approved indication for tesamorelin is limited to HIV-associated lipodystrophy. In clinical trials, tesamorelin produced a 15–18% reduction in visceral adipose tissue over 26 weeks at the approved 2 mg daily dose. In non-medical contexts, tesamorelin is commonly referenced for its fat-loss properties, though such use falls outside approved indications and should be approached with medical caution.
Key Benefits of Tesamorelin 5 mg
- FDA-approved GHRH analog with documented clinical trial data
- Lyophilized powder format for reconstitution flexibility
- Stimulates pulsatile endogenous GH release
- Studied for significant visceral fat reduction in clinical settings
- Manufactured by British Dragon
Formulation
Lyophilized Powder
Tesamorelin 5 mg is supplied as a lyophilized (freeze-dried) powder in a 2 mL vial. Reconstitution with an appropriate solvent is required before use in research or non-medical contexts.
Product Profile
Tesamorelin Profile
Tesamorelin is a 44-amino-acid peptide with a molecular weight of approximately 5,135 Da. Its sequence corresponds to the full length of endogenous human GHRH.
GHRH Analog
Tesamorelin belongs to the class of growth hormone-releasing hormone (GHRH) analogs, which stimulate GH secretion through direct activation of pituitary GHRH receptors. This mechanism is distinct from ghrelin receptor agonists such as ipamorelin, which act through a different receptor pathway.
Unlike exogenous recombinant human growth hormone, which directly introduces GH into circulation, tesamorelin stimulates the pituitary to release its own GH. Tesamorelin has a short half-life of approximately 26–38 minutes, producing a discrete GH pulse after administration. This pulsatile profile is often described as more physiologic than sustained GH elevation.
In clinical trials, tesamorelin 2 mg daily increased mean overnight GH secretion by approximately 70% and more than doubled IGF-1 levels. In non-medical bodybuilding contexts, tesamorelin is commonly referenced for visceral fat reduction and body composition support, though such use lacks controlled trial validation in healthy trained individuals.
Defining Characteristic
Short Half-Life, Pulsatile GH Release
Tesamorelin is distinguished by its short half-life and rapid clearance, which produces a discrete GH pulse rather than sustained elevation. This pulsatile profile is often described as more physiologic than longer-acting GHRH analogs such as CJC-1295.
Tesamorelin 5 mg vs Other British Dragon Preparations
British Dragon offers several peptide products targeting different aspects of endocrine and recovery biology. Within this lineup, Sermorelin is commonly discussed alongside tesamorelin for its GHRH-stimulating properties, though sermorelin is a shorter 29-amino-acid fragment with a different pharmacokinetic profile. The two peptides target the same receptor but differ in their duration of action.
For research focused on tissue recovery rather than GH stimulation, BPC 157 represents a different approach entirely, operating through angiogenic and cytoprotective mechanisms. Similarly, TB 500 addresses soft-tissue repair through a thymosin beta-4 fragment mechanism. These peptides are not interchangeable and target distinct biological pathways.
Dosage & Usage
Tesamorelin 5 mg Dosage & Usage
The information below is provided for educational reference only. Tesamorelin is a prescription medication approved for a specific medical indication. Its use for bodybuilding or performance enhancement falls outside approved indications and should be approached with medical caution.
Typical Dosage Ranges
The FDA-approved dose of tesamorelin is 2 mg administered subcutaneously once daily for HIV-associated lipodystrophy. This is the only clinically validated dose. In non-medical bodybuilding contexts, community protocols typically reference the same 2 mg daily dose, though some users report using lower doses (1–1.5 mg) to manage side effects, or splitting the dose into two 1 mg injections.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| FDA-approved (medical) | 2 mg | Once daily, subcutaneous |
| Non-medical lower-dose protocol | 1–1.5 mg | Once daily |
| Non-medical split protocol | 1 mg twice daily | Twice daily |
These ranges are community conventions. No controlled trials have evaluated tesamorelin in healthy trained individuals, and the dose-response relationship for body composition outcomes in non-medical contexts is not established.
Reconstitution & Handling
Tesamorelin 5 mg is supplied as a lyophilized powder and requires reconstitution before use. In non-medical contexts, bacteriostatic water is commonly used as the solvent. A 5 mg vial reconstituted with 5 mL of solvent yields a concentration of 1 mg/mL, meaning a 2 mg dose would require drawing 2 mL (200 units on a U-100 insulin syringe).
Reconstituted peptide is typically stored refrigerated and used within 7–14 days. Unreconstituted powder is more stable and should be kept sealed and protected from light.
Stacking & Cycle Considerations
In non-medical bodybuilding contexts, tesamorelin is sometimes combined with Sermorelin or other GHRH analogs, though there is no clinical evidence supporting combinations of GHRH analogs. Some users reference combining tesamorelin with Ipamorelin for potential synergistic GH release through different receptor pathways, though this represents an unstudied combination.
Cycle lengths in non-medical contexts vary widely, with some users reporting 12-week cycles followed by 4-week breaks, while clinical trial data shows sustained effects over 52 weeks of continuous use.
Important
Individual Response Varies
Tesamorelin dosing in medical practice is fixed at 2 mg daily based on clinical trial protocols. No established dosing protocol exists for non-medical use, and the information above is for educational reference only.
Safety & Information
Tesamorelin Safety Information
Tesamorelin is an FDA-approved prescription medication with specific indications and contraindications. Medical use requires appropriate diagnosis, clinical supervision, and ongoing monitoring.
Important Safety Information
Tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, or known hypersensitivity to tesamorelin or mannitol.
Tesamorelin is also contraindicated in women who are pregnant. If pregnancy occurs, tesamorelin should be discontinued. The FDA-approved indication is limited to HIV-infected patients with lipodystrophy; safety and efficacy in other populations have not been established.
Important
Non-Medical Use
Tesamorelin is approved only for a specific medical indication under clinical supervision. Non-medical use for bodybuilding or performance enhancement falls outside approved indications and is not supported by safety or efficacy data.
Potential Adverse Effects
The most common adverse reactions reported in clinical trials include injection site reactions (erythema, pruritus, pain, irritation, bruising), arthralgia, myalgia, paresthesia, and peripheral edema. These effects are generally mild to moderate and may resolve with continued treatment.
More serious adverse events include increased risk of glucose intolerance and diabetes, fluid retention, and serious allergic reactions including anaphylaxis. In clinical trials, fasting glucose elevations of 4–9% above baseline were observed.
Conditions Requiring Medical Evaluation
Blood glucose status should be carefully evaluated before initiating tesamorelin and monitored routinely during treatment. Patients with diabetes or prediabetes require close monitoring. IGF-1 levels should also be monitored, as prolonged elevations may have unknown effects on malignancy risk.
Pre-existing malignancy should be inactive and treatment completed before initiating tesamorelin therapy.
Monitoring During Therapy
Medically supervised tesamorelin therapy typically involves monitoring of IGF-1 levels, fasting glucose, and HbA1c. The FDA prescribing information recommends periodic glucose measurement. In clinical trials, IGF-1 levels were monitored and dose adjustments considered if levels exceeded the normal range for age and sex.
Product Care
Storage & Handling
Unreconstituted vials should be stored refrigerated between 2°C to 8°C (36°F to 46°F) and protected from light. Reconstituted solution should be used immediately; do not freeze or refrigerate after mixing. Keep out of reach of children.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Tesamorelin 5 mg is supplied through the official British Dragon distribution chain and shipped in original manufacturer packaging with discreet handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling. Products are supplied through the official British Dragon distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Tesamorelin 5 mg product, use the security code on the vial label and cross-check it on the British Dragon official site. Original packaging and manufacturer presentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Tesamorelin 5 mg Storage
Proper storage conditions help preserve peptide stability and integrity throughout shelf life.
Recommended Conditions
Store lyophilized powder refrigerated between 2°C to 8°C (36°F to 46°F) and protected from light. Keep vials in their original packaging until use.
Once reconstituted, use immediately and discard any unused solution. Do not freeze or refrigerate the reconstituted solution.
Keep out of reach of children. Follow proper handling practices.
Quick Reference
Do & Don't
- Do store powder refrigerated at 2–8°C
- Do keep in original packaging until use
- Do protect from light
- Don't freeze the powder
- Don't refrigerate reconstituted solution
- Don't use if solution appears cloudy or contains particles
Frequently Asked Questions
Tesamorelin 5 mg FAQ
Answers to common questions about Tesamorelin 5 mg, GHRH analogs, and research peptide handling.
What is Tesamorelin 5 mg used for?
Tesamorelin 5 mg contains tesamorelin acetate, a GHRH analog that stimulates endogenous growth hormone release. It is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. In non-medical bodybuilding contexts, it is commonly referenced for visceral fat reduction and body composition support, though such use falls outside approved indications.
How often should Tesamorelin 5 mg be injected?
The FDA-approved dosing schedule for tesamorelin is 2 mg administered subcutaneously once daily. This is the only clinically validated schedule. Non-medical community protocols typically follow the same once-daily schedule.
Does Tesamorelin 5 mg require PCT?
Tesamorelin does not suppress endogenous testosterone production and does not require post-cycle therapy in the way anabolic steroids do. However, any non-medical peptide use should be approached with caution given the absence of safety data for this context.
What does Tesamorelin do?
Tesamorelin is a GHRH analog that binds to GHRH receptors on the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone. In clinical trials, it produced significant reductions in visceral adipose tissue and increased lean body mass.
How long does Tesamorelin take to work?
In clinical trials, visceral fat changes were detectable at 13 weeks and continued through 26 weeks. Tesamorelin has a short half-life of approximately 26–38 minutes, with IGF-1 elevations persisting for about 24 hours after each dose.
Is Tesamorelin the best GHRH analog?
Tesamorelin is the only FDA-approved GHRH analog for its specific indication and has the most extensive clinical trial data among GHRH analogs. However, there is no universally “best” GHRH analog, and comparative data with other compounds is limited.
What is the difference between Tesamorelin 5 mg and Sermorelin?
Tesamorelin is a 44-amino-acid full-sequence GHRH analog, while Sermorelin is a shorter 29-amino-acid fragment. Both target the GHRH receptor, but tesamorelin has a longer half-life and more clinical trial data supporting its use.
What is the difference between Tesamorelin 5 mg and Ipamorelin?
Tesamorelin acts through the GHRH receptor, while Ipamorelin acts through the ghrelin receptor. They target different pathways and are sometimes combined in non-medical protocols, but they are not interchangeable.
Is 2 mg of Tesamorelin a lot?
2 mg is the FDA-approved daily dose of tesamorelin and the only clinically validated amount. Higher doses have not been shown to provide additional benefit and may increase side effect risk.
What strength is Tesamorelin 5 mg?
Tesamorelin 5 mg is labeled at 5 mg of tesamorelin acetate per vial. It is supplied as a lyophilized powder in a 2 mL vial.
How should Tesamorelin 5 mg be stored?
Store the lyophilized powder refrigerated at 2°C to 8°C and protected from light. Once reconstituted, use immediately; do not refrigerate or freeze the reconstituted solution.
Related Offers
British Dragon Pharmaceuticals
Product Information Compound Details
Active Substance Sermorelin Growth Hormone-Releasing Hormone (GHRH 1-29) Analog
5 mgStrength 5 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer British Dragon
British Dragon Pharmaceuticals
Product Information Compound Details
Active Substance GHK-Cu Copper Tripeptide-1 · Gly-His-Lys Copper Complex
50 mgStrength 50 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer British Dragon
British Dragon Pharmaceuticals
Product Information Compound Details
Active Substance MOTS-c Mitochondrial-Derived Peptide · 16 Amino Acids
10 mgStrength 10 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer British Dragon
British Dragon Pharmaceuticals
Product Information Compound Details
Active Substance Ipamorelin Selective Growth Hormone Secretagogue · Pentapeptide
5 mgStrength 5 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer British Dragon